Farther Finance Advisors’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
Other funds holding PLX
Farther Finance Advisors's PLX Position: Q3 2026 in Review
Farther Finance Advisors increased its Protalix BioTherapeutics (PLX) stake by 813% in Q3 2026, buying an estimated $2.18K and bringing the position to 986 shares worth $2.72K. The position accounts for ﹤0.01% of the portfolio, ranked #5292.
Farther Finance Advisors first reported a position in PLX in Q2 2024 and has held it in 3 quarters since. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.
- Farther Finance Advisors held 986 shares of Protalix BioTherapeutics worth $2.72K as of Q3 2026.
- Farther Finance Advisors bought 878 Protalix BioTherapeutics shares in Q3 2026, an estimated $2.18K.
- Protalix BioTherapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5292 holding.
- Farther Finance Advisors first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 3 quarters since.
- 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.
Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.